Prediction of response to neoadjuvant chemotherapy in patients with muscle-invasive urothelial bladder cancer: role of immune-related gene expression.

Hadeer Mahmoud, Abeer M Abd El-Aziz, Osama Ezzat, Hany Ibrahim Kenawy, Ahmed A Shokeir

Abstract read

In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hadeer MahmoudDepartment of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

Abeer M Abd El-AzizDepartment of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

Osama EzzatUrology Department, Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Hany Ibrahim KenawyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. hanykenawy@mans.edu.eg.

Ahmed A ShokeirUrology Department, Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Funding

Mansoura University Mu-Phar-23-24

6 · The paper itself

Abstract

This prospective study aimed at investigating the role of immune-related gene expression (GATA3, METTL3, ERCC2, PD-L1 and IFN-γ) in the prediction of response to platinum-based neoadjuvant chemotherapy (NAC) in treatment of muscle-invasive bladder cancer (MIBC). A total of 112 patients received four cycles of systemic cisplatin-based NAC and then were subjected to radiological and histopathological evaluation through taking bladder biopsy before surgery. Quantitative real-time RT-PCR assessed GATA3, METTL3 and ERCC2 mRNA expression in tissue samples. Immunohistochemical (IHC) staining was done for GATA3, PD-L1 and IFN-γ in tissue samples. Out of the 112 patients, only 104 completed the proposed protocol of systemic NAC and were included in the final analysis. Out of 104 patients, 43 (41.4%) were responders and the remaining 61 patients (58.6%) were assigned as non-responders. GATA3 and IFN-γ expressions were significantly higher in tumor tissue of the responders compared to non-responders. METTL3 and ERCC2 expressions were significantly lower in tumor tissue of the responders compared to non-responders, whereas, PD-L1 staining showed no significant difference between both groups. Our study suggests that GATA3, METTL3, ERCC2, and IFN-γ could serve as predictive biomarkers for NAC response in MIBC patients. Higher GATA3 and IFN-γ along with lower METTL3 and ERCC2 levels are positively correlated with better response to NAC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorUrinary Bladder NeoplasmsAgedB7-H1 AntigenCisplatinFemaleGATA3 Transcription FactorGene Expression Regulation, NeoplasticHumansInterferon-gammaMaleMethyltransferasesMiddle AgedNeoadjuvant TherapyPrognosisB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCisplatinERCC2 protein, humanGATA3 protein, humanGATA3 Transcription FactorInterferon-gammaMethyltransferasesXeroderma Pigmentosum Group D ProteinBladder cancerGene expressionImmunohistochemistryNeoadjuvant chemotherapy

Identifiers

PMID40736702

DOI10.1038/s41598-021-04678-7

PMCPMC12311079

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.